IMI 2 - Call 5
On 9 July 2015 IMI launched its 5th Call for proposals under IMI 2.
Call topics
- Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and health technology assessment bodies
- Diabetic kidney disease biomarkers (DKD-BM)
Inflammation and AD: modulating microglia function – focussing on TREM2 and CD33 - Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)
- Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease: phased expansion study
- From ApoE biology to validated Alzheimer’s disease targets
Further information can be found on the Call 5 - Stage 1 page
Questions?
- Webinars on IMI 2 - Call 5 are still ongoing. Sign up for the remaining webinars and download presentations for past webinars here
- Patients play an important role in IMI's projects and activities. For general advice for patients and other applicants on how best to meaningfully include patients in IMI projects, read our short guide . Specific ideas for patient involvement in the IMI 2 - Call 5 topics can be found here .
- Contact the IMI Programme Office
- Download the Call flyer
